HU1600270A2 - Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them - Google Patents

Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Info

Publication number
HU1600270A2
HU1600270A2 HU1600270A HU1600270A HU1600270A2 HU 1600270 A2 HU1600270 A2 HU 1600270A2 HU 1600270 A HU1600270 A HU 1600270A HU 1600270 A HU1600270 A HU 1600270A HU 1600270 A2 HU1600270 A2 HU 1600270A2
Authority
HU
Hungary
Prior art keywords
ivacaftor
complexes
salts
derivatives
preparation
Prior art date
Application number
HU1600270A
Inventor
Richard Balazs Karpati
Gergoe Patyi
Orsolya Basa-Denes
Erzsebet Reka Angi
Tamas Jordan
Tamas Solymosi
Glavinas Hristos Dr
Filipcsei Genoveva Dr
Original Assignee
Druggability Tech Ip Holdco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Druggability Tech Ip Holdco Ltd filed Critical Druggability Tech Ip Holdco Ltd
Priority to HU1600270A priority Critical patent/HU1600270A2/en
Publication of HU1600270A2 publication Critical patent/HU1600270A2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
HU1600270A 2016-04-25 2016-04-25 Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them HU1600270A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HU1600270A HU1600270A2 (en) 2016-04-25 2016-04-25 Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
HU1600270A HU1600270A2 (en) 2016-04-25 2016-04-25 Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
AU2017256180A AU2017256180A1 (en) 2016-04-25 2017-04-25 Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
JP2019506560A JP2019515029A (en) 2016-04-25 2017-04-25 Combined agent of ivacafitol and salts and derivatives of ivacafitol, preparation method thereof and pharmaceutical composition containing the same
CA3021944A CA3021944A1 (en) 2016-04-25 2017-04-25 Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
PCT/IB2017/052370 WO2017187336A1 (en) 2016-04-25 2017-04-25 Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN201780039667.4A CN109475548A (en) 2016-04-25 2017-04-25 According to cutting down the compound of Kato and its salt and derivative, preparation method and containing their pharmaceutical composition
EP17726697.0A EP3448383A1 (en) 2016-04-25 2017-04-25 Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IL262489A IL262489D0 (en) 2016-04-25 2018-10-21 Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
HU1600270A2 true HU1600270A2 (en) 2017-10-30

Family

ID=58800861

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1600270A HU1600270A2 (en) 2016-04-25 2016-04-25 Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Country Status (8)

Country Link
EP (1) EP3448383A1 (en)
JP (1) JP2019515029A (en)
CN (1) CN109475548A (en)
AU (1) AU2017256180A1 (en)
CA (1) CA3021944A1 (en)
HU (1) HU1600270A2 (en)
IL (1) IL262489D0 (en)
WO (1) WO2017187336A1 (en)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2810655C (en) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
BRPI0620960A2 (en) * 2005-12-28 2011-11-29 Vertex Pharmaceuticals Incorporated solid forms of N- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-didro-4-oxyquinoline-3-carboxamide
US20110251253A1 (en) 2010-03-25 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
CA2809263A1 (en) 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
MX2014010253A (en) 2012-02-27 2014-11-12 Vertex Pharma Pharmaceutical composition and administration thereof.
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
ES2694290T3 (en) 2012-11-02 2018-12-19 Vertex Pharmaceuticals Incorporated pharmaceutical compositions for the treatment of diseases mediated by CFTR
JP6146990B2 (en) 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド Deuterated CFTR enhancer
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
WO2014118805A1 (en) 2013-01-31 2014-08-07 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of ivacaftor and solvates thereof
WO2014125506A2 (en) 2013-02-15 2014-08-21 Laurus Labs Private Limited A process for the preparation of ivacaftor and its intermediates
CN104030981A (en) 2013-03-06 2014-09-10 上海特化医药科技有限公司 Preparation method and intermediate of Ivacaftor
HU1300647A2 (en) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015071841A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HU1300646A2 (en) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
SG10201803930QA (en) 2013-11-12 2018-07-30 Vertex Pharma Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
WO2015070336A1 (en) 2013-11-13 2015-05-21 Apotex Inc. Solid forms of ivacaftor and processes for the preparation thereof
HU1400075A2 (en) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical composition containing them
EP3131582B1 (en) 2014-04-15 2018-05-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CN104725314A (en) 2015-03-23 2015-06-24 上海皓元化学科技有限公司 New crystal form of Ivacaftor and preparation method thereof
CA3021752A1 (en) * 2015-06-11 2016-12-15 Aizant Drug Research Solutions Private Limited Nanoparticulate ivacaftor formulations

Also Published As

Publication number Publication date
CN109475548A (en) 2019-03-15
EP3448383A1 (en) 2019-03-06
CA3021944A1 (en) 2017-11-02
IL262489D0 (en) 2018-12-31
AU2017256180A1 (en) 2018-12-13
WO2017187336A4 (en) 2017-12-21
WO2017187336A1 (en) 2017-11-02
JP2019515029A (en) 2019-06-06

Similar Documents

Publication Publication Date Title
IL250890D0 (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase and pharmaceutical compositions containing them
EP3112364A4 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
FR3015483B1 (en) Novel thienopyrimidine derivatives, process for their preparation and pharmaceutical compositions containing same
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
IL267537D0 (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
IL251441D0 (en) Imidazo pyridine derivatives and pharmaceutical compositions containing them
FR3002733B1 (en) Novel salt of the abexinostat, the crystalline form associated with them, the process for preparing them and the pharmaceutical compositions containing them
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
IL261548D0 (en) 3-desoxy derivative and pharmaceutical compositions thereof
EP2978423A4 (en) Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
RU2018102365A (en) New hydroxide-etheric derivatives, method for producing them and pharmaceutical compositions containing them
EP3302426A4 (en) D2o stabilized pharmaceutical formulations
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
IL251302D0 (en) Boronic acid derivatives , their preparation and medicaments containing them
EP3231802A4 (en) Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof
HU1300647A2 (en) Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IL243226D0 (en) Pyrazole derivatives, their preparation and pharmaceutical composition containing them
HK1204623A1 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
EP3280408A4 (en) Process for the preparation of dicycloplatin
HK1232229A1 (en) Novel compound of 4-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof 4-
EA201890126A1 (en) New bicyclic derivatives, method of their production and pharmaceutical compositions containing them
SI3197867T1 (en) Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
IL256609D0 (en) Pyridine derivatives, their preparation and pharmaceutical compositions containing them
MX2017008518A (en) Isoquinoline compounds for the treatment of hiv.
HRP20171752T1 (en) Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same